DIMACHKIE , Mazen M. et al. Phase II Study of Arimoclomol in IBM FDA-OOPD . RRNMF Neuromuscular Journal, [S. l.], v. 2, n. 3, p. 104–142, 2021. DOI: 10.17161/rrnmf.v2i3.15728. Disponível em: https://journals.ku.edu/rrnmf/article/view/15728. Acesso em: 6 apr. 2025.